Review a lab product or service you have used:

Latest Winning Review

"Excellent improvement to the original Gilson Microman; particularly in user comfort (fits more easily in the hand, better suited to extended use). The new volume lock is also very good, stops any drift while in use."

EMD Millipore today announced the availability of its PluriSTEM™ Human ES/iPS Medium for the routine expansion of human embryonic and induced pluripotent stem cells in feeder- and serum-free conditions with less frequent feeding and cell culture time. It is the first human ES/iPS media to combine small molecule inhibitors with pluripotent specific growth factors and supplements to enable a less rigorous cell culture regiment. These features save researchers time and lead to lower costs.

The medium consists of fourteen components and is fully defined. The proprietary formulation includes Activin-A, TGFβ1, and b-FGF to promote stem cell self-renewal and potent small molecule combinations to inhibit unwanted spontaneous differentiation, as well as human serum albumin (HSA) to aid in overall colony morphology.

The culture of human ES/iPS cells has traditionally required feeding every day, including weekends, as well as significant technical expertise. This new medium addresses these challenges by providing an efficient and robust culture method that allows for feeding every other day, excluding weekends, saving both time and money. It also provides high viability and proliferation rates in single cell passaging.

"One of the main difficulties of traditional pluripotent stem cell culture is the time and expense required to achieve a successful undifferentiated culture. Our new PluriSTEM™ medium addresses this challenge by offering a simpler, less time-consuming culturing method," said Nick Asbrock, Stem Cell Product Manager in EMD Millipore's Bioscience business unit. "With the addition of the new medium to our stem cell product portfolio, EMD Millipore now offers a complete workflow solution for human ES and iPS culture systems, including proprietary reprogramming technologies, differentiation, and expansion media and kits for stem cell characterization."